Nitrates in silent ischemia.
In recent years it has become clear that episodes of transient myocardial ischemia commonly occur in patients with coronary artery disease in the absence of chest pain or angina equivalent. These episodes of "silent myocardial ischemia" are particularly well documented during continuous ambulatory electrocardiographic monitoring in daily life. Evidence suggests that these episodes represent true ischemia, and appear to be a marker of unfavorable outcome. While the pathophysiology is not completely understood, it appears as though the mechanisms of angina and silent ischemia are the same. Both forms of ischemia respond to conventional antianginal medication. While long-acting nitrates are effective in reducing or preventing myocardial ischemia, because of their propensity to cause tolerance they should be used intermittently and in association with either beta-blockers or calcium antagonists. Nitrates are safe and comparatively inexpensive, and will continue to play an important role in the treatment and prevention of angina. However, in the light of current knowledge, there is no specific indication for the treatment of silent ischemia by nitrates.
Purcell
H
H
Royal Brompton Hospital, London, UK.
Mulcahy
D
D
Fox
K
K
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000286:Administration, Sublingual; D002940:Circadian Rhythm / Q000187:drug effects / Q000502:physiology; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality / Q000503:physiopathology; D009566:Nitrates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010101:Oxygen Consumption / Q000187:drug effects; D010865:Pilot Projects; D011379:Prognosis
D003692:Delayed-Action Preparations; D009566:Nitrates